相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
David L. Wirta et al.
OPHTHALMOLOGY (2019)
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease
Damien F. Goldberg et al.
OPHTHALMOLOGY (2019)
Current market trends in anterior ocular inflammatory disease landscape
Rubba Shoukat Khan et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2019)
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Joseph Tauber et al.
CLINICAL OPHTHALMOLOGY (2018)
TFOS DEWS II Clinical Trial Design Report
Gary D. Novack et al.
OCULAR SURFACE (2017)
TFOS DEWS II Management and Therapy Report
Lyndon Jones et al.
OCULAR SURFACE (2017)
Lifitegrast for the Treatment of Dry Eye Disease Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)
Edward J. Holland et al.
OPHTHALMOLOGY (2017)
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial
Andrea Leonardi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2016)
Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease
Jose Manuel Benitez-Del-Castillo et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease Results of the Randomized Phase III OPUS-2 Study
Joseph Tauber et al.
OPHTHALMOLOGY (2015)
Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery
Kishore Cholkar et al.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2015)
Benefits of cetalkonium chloride cationic oil- in- water nanoemulsions for topical ophthalmic drug delivery
Philippe Daull et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2014)
Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease Results of the OPUS-1 Phase 3 Study
John D. Sheppard et al.
OPHTHALMOLOGY (2014)
Controlled ocular drug delivery with nanomicelles
Ravi D. Vaishya et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2014)
Dry Eye Disease Treatment: A Systematic Review of Published Trials and a Critical Appraisal of Therapeutic Strategies
Monica Alves et al.
OCULAR SURFACE (2013)
A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye
Charles P. Semba et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
The Economic Burden of Dry Eye Disease in the United States: A Decision Tree Analysis
Junhua Yu et al.
CORNEA (2011)
Nanomicellar formulations for sustained drug delivery: strategies and underlying principles
Ruchit Trivedi et al.
NANOMEDICINE (2010)
Cationic vectors in ocular drug delivery
L Rabinovich-Guilatt et al.
JOURNAL OF DRUG TARGETING (2004)
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease
K Sall et al.
OPHTHALMOLOGY (2000)
分享论文
